PDD与PTD方案对多发性骨髓瘤患者的疗效及IL-6水平的影响比较

doi:10.3969/j.issn.1006-6233.2017.06.02

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (1415 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the contrast PDD (Bortezomib + liposome adriamycin + dexamethasone) with PTD (Bortezomib + pirarubicin + dexamethasone) solutions in patients with multiple myeloma curative effect and the influence of the level of IL - 6. Methods: From January 2012 to January 2017, Selection of 38 cases of patients with MM.According to the different methods of treatment were divided into PDD group (19 cases), PTD group 19 cases.4 weeks after treatment, respectively observed before and after treatment of the two groups of clinical curative effect, before and after treatment serum levels of IL - 6,M protein,tumor cells and β₂-microglobulin and adverse reactions occured.Results: The PDD treatment group total remissio rate(sCR+CR) was 31.58% (6/19), compared with PTD group 5.26% (2/19), there's significant difference (P < 0.05).In the two groups after treatment than before treatment, serum levels of IL - 6 and PDD and below the PTD group, and had significant difference (P < 0.05).M protein PDD group after treatment, the tumor cells and β₂-microglobulin levels were below the PTD group, and had significant difference (P < 0.05).PDD and PTD group the incidence of hematologic adverse reactions with no significant difference (P > 0.05),but the incidence of alopecia and cardiac toxicity in PDD group was significantly lower than PTD group. Conclusion: The PDD therapy in the treatment of MM had better clinical curative effect, and can effectively improve the patients' serum level of IL - 6,M protein,tumor cells and β₂-microglobulin, better security, worthy of clinical popularization and application.

Key words： Multiple myeloma Bortezomib Liposome adriamycin Dexamethasone Interleukin 6

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.06.02 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I6/882

[1] Suzuki K, Sunami K, Ohashi K,et al.Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis[J].Blood Cancer,2017,7(3):540~541.
[2] 阙文忠,陈君敏.Ad-NK4增强人多发性骨髓瘤RPMI8226细胞对硼替佐米化疗敏感性的作用[J].中国实验血液学杂志,2016,24(4):1079~1085.
[3] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志,2015,54(12):1066~1070.
[4] 李新,陈世伦,黄仲夏,等.沙利度胺联合DVD方案治疗复发/难治型多发性骨髓瘤15例临床观察[J].中华内科杂志,2013,52(12):1055~1056.
[5] 骆林胜,林洁,丁香翠,等.VP与VAD方案治疗多发性骨髓瘤患者化疗后感染的研究[J].中华医院感染学杂志,2016,26(9):2088~2089.
[6] Sidana S, Narkhede M, Elson P,et al.Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain amyloidosis[J].PLoS One,2017,12(3):172996~172997.
[7] Zhao A, Kong F, Liu CJ,et al.Tumor cell-derived microvesicles induced not epithelial-mesenchymal transition but apoptosis in human proximal tubular (HK-2) cells: implications for renal impairment in multiple myeloma[J].Int Mol Sci,2017,18(3):513~514.
[8] 鲍立,黄晓军.硼替佐米周用药化疗方案治疗初诊多发性骨髓瘤效果及安全性[J].中国医药,2016,11(2):246~250.
[9] 郝倩云,陈欢,刘开彦,等.BD方案与PAD方案在多发性骨髓瘤中的队列研究[J].中华内科杂志,2016,55(9):689~694.
[10] 马玲,傅琤琤,刘辉,等.PDD与PAD方案治疗初治多发性骨髓瘤患者的疗效和安全性比较[J].中华血液学杂志,2015,36(4):340~343.
[11] 李新,孙万军,靳凤艳,等.20例存活7年以上多发性骨髓瘤患者临床观察[J].肿瘤学杂志,2014,20(7):574~577.